A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors

• Published in: International journal of molecular sciences Vol. 23; no. 12; p. 6468
• Main Authors: Jo, Seri, Signorile, Luca, Kim, Suwon, Kim, Mi-Sun, Huertas, Oscar, Insa, Raúl, Reig, Núria, Shin, Dong Hae
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 09.06.2022; MDPI
• Subjects: antiviral; Artificial intelligence; Chemical bonds; Clinical trials; Coronaviruses; COVID-19; Cytotoxicity; drug repurposing; Drugs; FDA approval; fret; Infections; inhibitory compounds; Ligands; Middle East respiratory syndrome; Protease; Protease inhibitors; Proteinase; Proteinase inhibitors; Respiratory diseases; SARS-CoV-2 3CL protease; Severe acute respiratory syndrome coronavirus 2; Viral diseases

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wreaked havoc all over the world. Although vaccines for the disease have recently become available and started to be administered to the population in various countries, there i...